Published: 2022 June 06
Crohn’s Disease Market
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Crohn’s Disease Market  is segmented By Drug Class (Anti-diarrheal, Anti-inflammatory drugs, Immunosuppressors, Antibiotics, Biologics, Pain relievers), By Route of Administration (Injectable, Oral), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Crohn’s Disease Market is expected to reach at a high CAGR of 3.5% during the forecast period (2022-2029). 

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Crohn's disease is caused by a combination of factors involving genetics, the environment, and an overactive immune system.

North America region holds the largest market share in the global Crohn's disease market

North America is dominating the global Crohn's Disease therapeutic market due to the high incidence rate of the disease and notable increase in the regulatory approval of Crohn's disease therapeutics in recent years. According to the Centers for Disease Control and Prevention, Crohn's disease in North America was 319 per 100,000 persons, whereas, in Europe, it was 322 per 100,000 persons in 2017.

Therefore, the Crohn's disease market is projected to witness key trends such as increased preference for symptomatic drugs and therapeutic over surgeries, better disease management for inflammatory bowel diseases like Crohn's disease, and the arrival of improved drugs in the market due to better investments in R&D programs, prevailing the market.

For instance, in October 2018, Sandoz, a Novartis division, received the FDA approval for its biosimilar, Hyrimoz (adalimumab-adaz). The product received FDA approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC) and plaque psoriasis (Ps).

Market Dynamics

The increasing number of drug therapies for the disease and advanced technologies used for better diagnosis and treatment drive the Crohn’s disease market. The growing number of patients and efforts taken by the government to improve the healthcare infrastructures are also fueling the demand for Crohn’s disease market.

The increasing prevalence of inflammatory bowel disease (IBD) drive the market growth

The increasing number of drug therapies for the disease and advanced technologies used for better diagnosis and treatment drive the Crohn's disease market. For instance, according to World Health Organization (WHO), colder-climate regions and urban areas have a greater rate of IBD than those of warmer climates and rural areas. Globally, the incidence of IBD is approximately 0.5-24.5 cases per 100,000 for ulcerative colitis and 0.1-16 cases per 100,000 for Crohn's disease. The prevalence of IBD is 396 cases per 100,000 persons annually. WHO's regional analysis on IBD incidence states approximately 1.6 million Americans are suffering from Crohn's disease or ulcerative colitis. 70,000 new cases of IBD are diagnosed in the US each year. This factor will drive the market growth in the forecast period.

New product development & approvals will drive Crohn's disease market

Growing awareness of the disease, linked with increasing initiatives by regulatory bodies to develop novel treatment options, is estimated to provide the market with high growth potential.

For instance, in collaboration with Pfizer, the American Gastroenterological Association (AGA) supports research projects related to inflammatory bowel diseases and has offered three grants in their name. In addition, the Crohn's & Colitis Foundation, European Federation of Crohn's & Ulcerative Colitis Associations, and American Autoimmune Related Diseases Association provide funds for research.

Key players have made significant investments in R&D, and various pipeline products are in different stages of clinical approvals and likely to be commercialized during the forecast period. Allergan and  AstraZeneca are together developing the MEDI2070 interleukin-23 monoclonal antibody against Crohn's disease and ulcerative colitis. MEDI2070 is currently in phase IIb of the clinical trial for average to severe Crohn's disease and in phase II for ulcerative colitis. Pfizer's PF-00547659 and Celgene's Ozanimod are in phase II and phase III clinical trials for Crohn's Disease and ulcerative colitis. Additionally, the new launch and approval of novel drugs in North America, Europe, and Japan are predicted to drive market growth.

The high cost of treatment procedures is likely to hamper the market growth

However, factors such as costly treatment procedures, the absence of early treatment due to unawareness of the disease, and the patent expiry of the blockbuster drug are the restraints that will hamper the market growth.

COVID-19 Impact Analysis

COVID-19 pandemic is a continuing global health crisis due to severe acute respiratory syndrome coronavirus two and provides vital challenges for patient care in Crohn's disease. There is currently no indication for an increased number of COVID-19 cases in Crohn's disease; a recent study suggesting reduced disease activity in Crohn's disease requires further investigations. However, some medications for Crohn's may change or suppress the immune system, which may raise a person's risk. These drugs involve steroids, such as prednisone, methylprednisolone, and hydrocortisone. These factors will hamper the market in the forecast period.

Crohn’s Disease Market Scope



Market CAGR


Segments Covered

 By Drug Class, By Route of Administration, By Distribution Channel,  and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

Segment Analysis 

The dominant biologics market is mainly due to the regulative approval for novel biologics and the recent surge in vital alliances between companies related to biologics used to treat Crohn’s disease. Biologics are prescription drugs made from living organisms. Biologics work on the immune system. They target specific proteins in the body that cause inflammation.

These treatments are called biologics because, unlike chemical medications, they are made out of materials found in life. Biologic therapies are usually prescribed in people with more severe Crohn’s symptoms who haven’t found relief with other methods. Most biologics for Crohn’s disease block a protein called tumor necrosis factor (TNF). Other biologics block immune cells called integrins, and others act on proteins called interleukin-23 (IL-23) and interleukin-12 (IL-12). This is how biological therapies stop inflammation in the gut. These factors are driving the segment growth in the forecast period.

For instance, in April 2018, Mylan N.V., partnered with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize Fujifilm’s Humira (adalimumab) biosimilar. Mylan will leverage its regulatory platform to seek approval and commercialize the product in Europe.

Competitive Landscape

The Crohn's disease market is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include GlaxoSmithKline plc. F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, Shaanxi Yuantai Biological Technology Co., Ltd. HEFEI JOYE IMPORT & EXPORT CO., LTD. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Crohn's disease market globally.    

 Crohn’s Disease Market Key Companies to Watch

Merck & Co.

Overview: Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.

Product Portfolio: The Company offers focused on Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders.

Key Development: In July 2017, Merck introduced RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) in the U.S. RENFLEXIS is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease.

Trending Topics

Antinauseants Market

Achalasia Treatment Market

Esomeprazole Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy